Get the Stockscreener App
21.83
1.21%
0.26
After Hours:
21.83
Pulse Biosciences Inc stock is traded at $21.83, with a volume of 254.10K.
It is up +1.21% in the last 24 hours and down -5.13% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$21.57
Open:
$21.58
24h Volume:
254.10K
Relative Volume:
0.81
Market Cap:
$1.48B
Revenue:
$350.00K
Net Income/Loss:
$-72.78M
P/E Ratio:
-20.21
EPS:
-1.08
Net Cash Flow:
$-54.46M
1W Performance:
+19.58%
1M Performance:
-5.13%
6M Performance:
+31.19%
1Y Performance:
+29.10%
1-Day Range:
$21.23
$22.74
1-Week Range:
$18.00
$22.82
52-Week Range:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
21.83 | 1.47B | 350.00K | -72.78M | -54.46M | -1.08 |
|
ISRG
Intuitive Surgical Inc
|
483.46 | 167.68B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
160.27 | 45.33B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
77.79 | 37.69B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
41.75 | 33.65B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
230.61 | 33.63B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Is Pulse Biosciences’ (PLSE) Thyroid Cancer Feasibility Study a Prelude to a Broader Platform Strategy? - Yahoo Finance
A Look At Pulse Biosciences (PLSE) Valuation As Thyroid Cancer Feasibility Study Begins - Yahoo Finance
Pulse Biosciences enrolls first patients in thyroid cancer study By Investing.com - Investing.com Nigeria
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And DCF Estimate Gap - simplywall.st
Responsive Playbooks and the PLSE Inflection - Stock Traders Daily
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Swings - Sahm
Pulse Biosciences enrolls first patients in thyroid cancer study - Investing.com South Africa
Pulse Biosciences Launches Thyroid Cancer Feasibility Study - TipRanks
Pulse Biosciences, Inc. Announces First Enrollments in Feasibilit - The National Law Review
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology - The Joplin Globe
Pulse Biosciences (NASDAQ:PLSE) Trading 8% HigherWhat's Next? - MarketBeat
Breakout Move: Can Pulse Biosciences Inc continue delivering strong returnsMarket Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Durable Thyroid Nodule Ablation Data Could Be A Game Changer For Pulse Biosciences (PLSE) - Sahm
Pulse Biosciences (PLSE) Reports Promising Long-Term Outcomes fo - GuruFocus
Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn - TipRanks
Pulse Biosciences Announces Long-Term Clinical Data for nPulse Vybrance Percutaneous Electrode System in Benign Thyroid Nodule Ablation 71314 - Minichart
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Investing News Network
Pulse Biosciences Reports Durable Thyroid Nodule Ablation Results - TipRanks
Pulse Biosciences (PLSE) reports 74% benign thyroid nodule reduction in nsPFA study - Stock Titan
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Business Wire
Why Pulse Biosciences Inc. stock could be next big winnerEarnings Recap Summary & Fast Entry and Exit Trade Plans - Naître et grandir
How strong is Pulse Biosciences Inc. (6L8) stock earnings growthDividend Hike & Low Volatility Stock Recommendations - Naître et grandir
Pulse Biosciences' nPulse Vybrance System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - Investing News Network
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Momentum - simplywall.st
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - The Joplin Globe
Pulse Biosciences at TD Cowen Conference: NSPFA Technology Shines - Investing.com
FinancialContentPulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting - FinancialContent
PLSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulse Biosciences (NASDAQ:PLSE) Stock Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Pulse Biosciences Highlights nPulse Cardiac Ablation Progress - TipRanks
Pulse Biosciences posts updated investor deck highlighting nPulse cardiac catheter and strengthened EP focus - TradingView
Pulse Biosciences (NASDAQ: PLSE) releases updated March 2026 investor deck - Stock Titan
Pulse Biosciences, Inc (PLSE) Stock Analysis: Is A 59% Upside Within Reach? - DirectorsTalk Interviews
Market Wrap: Does Pulse Biosciences Inc have strong fundamentalsWeekly Earnings Recap & Weekly Top Stock Performers List - baoquankhu1.vn
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE) clarifies disclosure on CCO Kevin Danahy’s resignation - Stock Titan
Pulse Biosciences Executive Sells 60,000 Shares - TradingView
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And Cash Flow Forecasts? - Yahoo Finance
Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding PlansHas The Bull Case Changed? - simplywall.st
PLSE Should I Buy - Intellectia AI
Pulse Biosciences chief commercial officer resigns effective immediately - Investing.com Nigeria
Pulse Biosciences Announces Resignation of Chief Commercial Officer - TipRanks
Chief Commercial Officer exits Pulse Biosciences (PLSE) with no stated dispute - Stock Titan
US med-tech companies bullish about 2026 - bioworld.com
Is Pulse Biosciences (PLSE) Share Price Justified After Recent Volatility In Healthcare Sentiment - simplywall.st
Pulse Biosciences (PLSE) Price Target Increased by 27.66% to 30.60 - Nasdaq
Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a 48.59% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ETF Watch: Will Perfect Corp Equity Warrant face regulatory challenges2025 Stock Rankings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Pulse Biosciences CCO Danahy sells $118k in PLSE stock By Investing.com - Investing.com Canada
Kevin Patrick Danahy Sells 5,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock - MarketBeat
Pulse Biosciences (PLSE) CCO exercises options and sells 5,000 shares - Stock Titan
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):